ImmixBio Announces FDA Orphan Drug Designation for IMX-110 for the Treatment of Soft Tissue Sarcoma News provided byImmix Biopharma, Inc.Sep 30, 2021, 08:38 ET LOS ANGELES, Sept. 30, 2021 /PRNewswire/ — Immix Biopharma, Inc. (“ImmixBio”), a biotechnology company pioneering Tissue Specific Therapeutics (TSTx)TM for oncology and […]
ImmixBio Announces Clinical Trial and Supply Agreement with BeiGene to Evaluate Combination of IMX-110 and Tislelizumab in Solid Tumors Novel Approach Combining ImmixBio Tissue Specific Therapeutics (TSTx)™ with Immunotherapies Could Expand the Population Of Cancer Patients Experiencing Extended Remissions News provided byImmix Biopharma, Inc.Aug 27, 2021, […]
ImmixBio Announces Dr. Galit Lahav of Harvard Medical School Joins Scientific Advisory Board Dr. Galit Lahav, pioneer of understanding why individual human cancer cells often show different responses to the same treatment (including p53 and NF-kB signaling dynamics), and identifying new therapies that will increase the […]
ImmixBio Announces Dr. George W. Sledge of Stanford University Medical Center Joins Scientific Advisory Board Dr. George W. Sledge, former ASCO president, pioneering clinical investigator of multiple approved cancer therapeutics including multi-kinase inhibitor abemaciclib (marketed as VERZENIO® by Eli Lilly) and paclitaxel News provided byImmix Biopharma, […]
ImmixBio Announces Dr. Jane Buchan Joins Board of Directors News provided byImmix Biopharma, Inc. Jul 28, 2021, 08:48 ET LOS ANGELES, July 28, 2021 /PRNewswire/ — Immix Biopharma, Inc. (“ImmixBio”), a biotechnology company pioneering Tissue Specific Therapeutics (TSTx)™ for oncology and inflammation, today announced that world-renown institutional […]
ImmixBio Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering News provided byImmix Biopharma, Inc.Jul 23, 2021, 08:38 ET LOS ANGELES, July 23, 2021 /PRNewswire/ — Immix Biopharma, Inc. today announced that it has confidentially submitted a draft registration statement on Form S-1 […]
ImmixBio Announces Helen C. Adams Joins Board of Directors News provided by Immix Biopharma, Inc. Jul 13, 2021, 08:11 ET LOS ANGELES, July 13, 2021 /PRNewswire/ — Immix Biopharma, Inc. (“ImmixBio”), a biotechnology company pioneering Tissue-Specific Therapeutics (TSTx)â„¢ for oncology and inflammation, today announced that accounting […]
ImmixBio Announces Gabriel Morris as Chief Financial Officer and a Member of the Board of Directors News provided byImmix Biopharma, Inc.Jul 06, 2021, 08:44 ET LOS ANGELES, July 6, 2021 /PRNewswire/ — Immix Biopharma, Inc. (“ImmixBio”), a biotechnology company pioneering Tissue-Specific Therapeutics (TSTx)TM for oncology and […]
LOS ANGELES, Feb. 4, 2020 — Immix Biopharma, Inc., announced today that the first patient in the USA was dosed successfully in its flagship phase 1b/2a clinical trial testing Imx-110 in patients with refractory solid tumors. To-date, the trial has accrued patients across tumor types. The […]
Immix adds Biotech VC Mesa Verde to Investor Syndicate and Receives IRB Approval to Enroll Patients in Phase 1b/2a Cancer Study in the United States LOS ANGELES, Dec. 17, 2019 /PRNewswire/ Immix Biopharma, Inc., announced today the first closing of a convertible note financing to support […]